SlideShare a Scribd company logo
1 of 5
Download to read offline
BURNS:
The pharmacokinetics and
pharmacodynamics of drugs are
significantly altered in the burn
patient, and the burn patient
population shows wide inter- and
intraindividual variation in drug
handling.
• Burn injury evolves in two phases.
• The first phase corresponds to the burn shock,
which occurs during the first 48 hours after
thermal injury.
In this phase, hypovolaemia, oedema,
hypoalbuminaemia and a low
glomerular filtration rate are observed,
which result in a slower rate of drug
distribution and lower renal clearance.
• The second phase (beyond 48 hours after
injury) is a hyperdynamic state with high
blood flow in the kidneys and liver, an
increased α1-acid-glycoprotein level and loss
of the drug with exudate leakage. As a result,
protein binding, drug distribution and
clearance may be altered.
• protein binding, drug distribution and clearance
may be altered.
• Because of the alteration in these variables, wide
intraindividual variation of pharmacokinetic
parameters occurs depending upon the time
since thermal injury and fluid resuscitation.
• Interindividual variations may be correlated with
the percentage of the body surface area that is
burnt,

More Related Content

Similar to ppt.pptx

Hepatic disease.pptx
Hepatic disease.pptxHepatic disease.pptx
Hepatic disease.pptxZeshanKazmi2
 
Nursing management of Burns
Nursing management of BurnsNursing management of Burns
Nursing management of BurnsAseem Badarudeen
 
Therapeutic Drug Monitoring (TDM) | Criteria and Indications of TDM | Why TDM...
Therapeutic Drug Monitoring (TDM) | Criteria and Indications of TDM | Why TDM...Therapeutic Drug Monitoring (TDM) | Criteria and Indications of TDM | Why TDM...
Therapeutic Drug Monitoring (TDM) | Criteria and Indications of TDM | Why TDM...Shaikh Abusufyan
 
Pharmacokinetics absorption and distribution
Pharmacokinetics absorption and distributionPharmacokinetics absorption and distribution
Pharmacokinetics absorption and distributionsumitmahato20
 
Kaplan_TopicEssentials_Pharmacology.pdf
Kaplan_TopicEssentials_Pharmacology.pdfKaplan_TopicEssentials_Pharmacology.pdf
Kaplan_TopicEssentials_Pharmacology.pdfNorhanKhaled15
 
144_2017_01_08!01_34_23_PM.pptx
144_2017_01_08!01_34_23_PM.pptx144_2017_01_08!01_34_23_PM.pptx
144_2017_01_08!01_34_23_PM.pptxImedMAATOUK3
 
Drug distribution and its clinical significance
Drug distribution and its clinical significanceDrug distribution and its clinical significance
Drug distribution and its clinical significanceDeepakPandey379
 
Pharmacokinetics variations in Disease States.
Pharmacokinetics variations in Disease States.Pharmacokinetics variations in Disease States.
Pharmacokinetics variations in Disease States.Faizan Akram
 
Half Life of Drug, Introduction, types.pptx
Half Life of Drug, Introduction, types.pptxHalf Life of Drug, Introduction, types.pptx
Half Life of Drug, Introduction, types.pptxrphsadiazuberi
 
Pharmacokinetics class 2
Pharmacokinetics   class 2Pharmacokinetics   class 2
Pharmacokinetics class 2candyshridhar24
 
Clinical Trials,Hypersenstivity,types of drug interactions.pptx
Clinical Trials,Hypersenstivity,types of drug interactions.pptxClinical Trials,Hypersenstivity,types of drug interactions.pptx
Clinical Trials,Hypersenstivity,types of drug interactions.pptxDrNailaRiasatAli
 
Excretion of drugs and kinetics of elimination
Excretion of drugs and kinetics of eliminationExcretion of drugs and kinetics of elimination
Excretion of drugs and kinetics of eliminationmohamed sanooz
 
metabolic response o surgery for aneasthseia.pptx
metabolic response o surgery for aneasthseia.pptxmetabolic response o surgery for aneasthseia.pptx
metabolic response o surgery for aneasthseia.pptxNuunPh
 

Similar to ppt.pptx (20)

Hepatic disease.pptx
Hepatic disease.pptxHepatic disease.pptx
Hepatic disease.pptx
 
Prednisone as antitumor (anticancer)
Prednisone as antitumor (anticancer)Prednisone as antitumor (anticancer)
Prednisone as antitumor (anticancer)
 
Nursing management of Burns
Nursing management of BurnsNursing management of Burns
Nursing management of Burns
 
Therapeutic Drug Monitoring (TDM) | Criteria and Indications of TDM | Why TDM...
Therapeutic Drug Monitoring (TDM) | Criteria and Indications of TDM | Why TDM...Therapeutic Drug Monitoring (TDM) | Criteria and Indications of TDM | Why TDM...
Therapeutic Drug Monitoring (TDM) | Criteria and Indications of TDM | Why TDM...
 
Pharmacokinetics absorption and distribution
Pharmacokinetics absorption and distributionPharmacokinetics absorption and distribution
Pharmacokinetics absorption and distribution
 
تابع محاضرة ال liver.pdf
تابع محاضرة ال liver.pdfتابع محاضرة ال liver.pdf
تابع محاضرة ال liver.pdf
 
Chronopharmacokinetics
ChronopharmacokineticsChronopharmacokinetics
Chronopharmacokinetics
 
Chronopharmacokinetics..
Chronopharmacokinetics..Chronopharmacokinetics..
Chronopharmacokinetics..
 
Kaplan_TopicEssentials_Pharmacology.pdf
Kaplan_TopicEssentials_Pharmacology.pdfKaplan_TopicEssentials_Pharmacology.pdf
Kaplan_TopicEssentials_Pharmacology.pdf
 
144_2017_01_08!01_34_23_PM.pptx
144_2017_01_08!01_34_23_PM.pptx144_2017_01_08!01_34_23_PM.pptx
144_2017_01_08!01_34_23_PM.pptx
 
Drug distribution and its clinical significance
Drug distribution and its clinical significanceDrug distribution and its clinical significance
Drug distribution and its clinical significance
 
Adverse drug reaction monitoring
Adverse drug reaction monitoringAdverse drug reaction monitoring
Adverse drug reaction monitoring
 
Pharmacokinetics variations in Disease States.
Pharmacokinetics variations in Disease States.Pharmacokinetics variations in Disease States.
Pharmacokinetics variations in Disease States.
 
Half Life of Drug, Introduction, types.pptx
Half Life of Drug, Introduction, types.pptxHalf Life of Drug, Introduction, types.pptx
Half Life of Drug, Introduction, types.pptx
 
Pharmacokinetics class 2
Pharmacokinetics   class 2Pharmacokinetics   class 2
Pharmacokinetics class 2
 
Clinical Trials,Hypersenstivity,types of drug interactions.pptx
Clinical Trials,Hypersenstivity,types of drug interactions.pptxClinical Trials,Hypersenstivity,types of drug interactions.pptx
Clinical Trials,Hypersenstivity,types of drug interactions.pptx
 
Excretion of drugs and kinetics of elimination
Excretion of drugs and kinetics of eliminationExcretion of drugs and kinetics of elimination
Excretion of drugs and kinetics of elimination
 
Pharmacovigila final 2
Pharmacovigila final 2Pharmacovigila final 2
Pharmacovigila final 2
 
Cocaina intox. 2012. crit care
Cocaina intox. 2012. crit careCocaina intox. 2012. crit care
Cocaina intox. 2012. crit care
 
metabolic response o surgery for aneasthseia.pptx
metabolic response o surgery for aneasthseia.pptxmetabolic response o surgery for aneasthseia.pptx
metabolic response o surgery for aneasthseia.pptx
 

ppt.pptx

  • 1. BURNS: The pharmacokinetics and pharmacodynamics of drugs are significantly altered in the burn patient, and the burn patient population shows wide inter- and intraindividual variation in drug handling.
  • 2. • Burn injury evolves in two phases. • The first phase corresponds to the burn shock, which occurs during the first 48 hours after thermal injury.
  • 3. In this phase, hypovolaemia, oedema, hypoalbuminaemia and a low glomerular filtration rate are observed, which result in a slower rate of drug distribution and lower renal clearance.
  • 4. • The second phase (beyond 48 hours after injury) is a hyperdynamic state with high blood flow in the kidneys and liver, an increased α1-acid-glycoprotein level and loss of the drug with exudate leakage. As a result, protein binding, drug distribution and clearance may be altered.
  • 5. • protein binding, drug distribution and clearance may be altered. • Because of the alteration in these variables, wide intraindividual variation of pharmacokinetic parameters occurs depending upon the time since thermal injury and fluid resuscitation. • Interindividual variations may be correlated with the percentage of the body surface area that is burnt,